Fennec Financial Statements From 2010 to 2025

FENC Stock  USD 6.57  0.25  3.96%   
Fennec Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Fennec Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Fennec Pharmaceuticals financial statements helps investors assess Fennec Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Fennec Pharmaceuticals' valuation are summarized below:
Gross Profit
44.4 M
Profit Margin
(0)
Market Capitalization
180 M
Enterprise Value Revenue
3.6334
Revenue
47.5 M
We have found one hundred twenty available fundamental signals for Fennec Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of Fennec Pharmaceuticals' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Fennec Pharmaceuticals Total Revenue

25.66 Million

Check Fennec Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fennec Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 313.5 K or Interest Expense of 4.1 M, as well as many indicators such as Price To Sales Ratio of 15.33, Dividend Yield of 0.0 or Days Sales Outstanding of 165. Fennec financial statements analysis is a perfect complement when working with Fennec Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Fennec Pharmaceuticals Correlation against competitors.
For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.

Fennec Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16.1 M30.9 M14.8 M
Slightly volatile
Short and Long Term Debt Total37.4 M35.6 M11.5 M
Slightly volatile
Other Current Liabilities4.5 M4.3 M2.2 M
Very volatile
Total Current Liabilities9.1 M8.7 M3.7 M
Slightly volatile
Other Liabilities284.1 K299 K3.5 M
Slightly volatile
Property Plant And Equipment Net552.5 K484.1 K419.8 K
Slightly volatile
Accounts Payable4.6 M4.3 M1.4 M
Slightly volatile
Cash11 M15.3 M12.3 M
Slightly volatile
Cash And Short Term Investments11.7 M15.3 M12.3 M
Slightly volatile
Common Stock Shares Outstanding32.1 M30.6 M17.5 M
Slightly volatile
Liabilities And Stockholders Equity16.1 M30.9 M14.8 M
Slightly volatile
Non Current Liabilities Total37.4 M35.6 M8.8 M
Slightly volatile
Other Current Assets3.2 MM732.3 K
Slightly volatile
Other Stockholder Equity38.1 M71.4 M44.5 M
Slightly volatile
Total Liabilities46.5 M44.3 M12 M
Slightly volatile
Property Plant And Equipment Gross552.5 K484.1 K419.8 K
Slightly volatile
Total Current Assets32.4 M30.9 M15.8 M
Slightly volatile
Short Term Debt18 K18.9 K646.4 K
Slightly volatile
Common Stock174.3 M166 M102.4 M
Slightly volatile
Capital Surpluse49.4 M61.2 M46.2 M
Slightly volatile
Net Invested Capital17.3 M17.4 M23.3 M
Slightly volatile
Net Working Capital17.2 M17.4 M23.3 M
Slightly volatile
Capital Stock143.2 M166 M121.3 M
Slightly volatile
Long Term Debt TotalM4.5 M4.9 M
Slightly volatile

Fennec Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative24.9 M23.7 M8.9 M
Slightly volatile
Other Operating Expenses41.1 M39.1 M13.9 M
Slightly volatile
Research Development47.9 K50.4 KM
Pretty Stable
Total Operating Expenses39.6 M37.7 M13.6 M
Slightly volatile
Interest Income262.7 K431.1 K612.7 K
Slightly volatile
Reconciled Depreciation202 K330.1 K126.6 K
Slightly volatile
Selling And Marketing Expenses8.2 M13.9 M4.4 M
Slightly volatile

Fennec Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow28.7 M27.3 M13.7 M
Slightly volatile
End Period Cash Flow11 M15.3 M12.3 M
Slightly volatile
Stock Based Compensation6.5 M6.2 M2.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio15.3316.13596.3 K
Slightly volatile
Days Sales Outstanding165174M
Slightly volatile
Average Payables430.7 K484.6 K528.3 K
Slightly volatile
Stock Based Compensation To Revenue0.280.2912.0219
Slightly volatile
Capex To Depreciation0.09990.110.1263
Slightly volatile
EV To Sales17.9517.09591.4 K
Slightly volatile
Sales General And Administrative To Revenue1.061.1154.0106
Slightly volatile
Average Inventory226.8 K216 K222.7 K
Slightly volatile
Research And Ddevelopement To Revenue0.00290.00386.9 K
Slightly volatile
Cash Per Share0.550.570.6464
Slightly volatile
Intangibles To Total Assets0.440.540.5801
Pretty Stable
Current Ratio5.113.26.134
Slightly volatile
Receivables Turnover2.282.171.174
Slightly volatile
Average Receivables120.4 K92.4 K87.2 K
Very volatile
Revenue Per Share0.760.720.1543
Slightly volatile
Interest Debt Per Share1.221.160.3104
Slightly volatile
Debt To Assets1.091.040.4216
Slightly volatile
Operating Cycle848893M
Slightly volatile
Long Term Debt To Capitalization1.511.440.5454
Slightly volatile
Total Debt To Capitalization1.511.440.5542
Slightly volatile
Quick Ratio5.062.946.089
Slightly volatile
Net Income Per E B T0.770.940.9688
Pretty Stable
Cash Ratio1.51.585.9796
Pretty Stable
Days Of Sales Outstanding165174M
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0203
Slightly volatile
Fixed Asset Turnover0.00.00.0
Slightly volatile
Debt Ratio1.091.040.4216
Slightly volatile
Price Sales Ratio15.3316.13596.3 K
Slightly volatile
Asset Turnover0.750.710.1512
Slightly volatile
Gross Profit Margin1.031.085.2 K
Slightly volatile

Fennec Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap145.6 M131.6 M135.3 M
Slightly volatile
Enterprise Value121.1 M113.1 M112.5 M
Slightly volatile

Fennec Fundamental Market Drivers

Forward Price Earnings11.9332
Cash And Short Term Investments13.3 M

Fennec Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fennec Pharmaceuticals Financial Statements

Fennec Pharmaceuticals stakeholders use historical fundamental indicators, such as Fennec Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Fennec Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fennec Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Fennec Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fennec Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-18.9 K-18 K
Total Revenue24.4 M25.7 M
Cost Of Revenue1.4 M1.5 M
Stock Based Compensation To Revenue 0.29  0.28 
Sales General And Administrative To Revenue 1.11  1.06 
Revenue Per Share 0.72  0.76 
Ebit Per Revenue(0.54)(0.57)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:
Check out the analysis of Fennec Pharmaceuticals Correlation against competitors.
For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
1.742
Quarterly Revenue Growth
(0.19)
Return On Assets
0.0447
Return On Equity
(10.06)
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.